Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 81-83
DOI: 10.58347/tml.2026.1755a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved orforglipron (Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss. The Medical Letter on Drugs and Therapeutics, 68(1755), 81-83. https://doi.org/10.58347/tml.2026.1755a
Vancouver
Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):81-83. doi:10.58347/tml.2026.1755a
BibTeX
@article{euvimed2026,
title = {Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1755},
pages = {81--83},
doi = {10.58347/tml.2026.1755a}
}
EUVIMED